Onkologie. 2016:10(1):49-51 | DOI: 10.36290/xon.2016.011

Triple negative breast cancer treated with bevacizumab

Jana Pukyová, David Šulc, Martina Chodacká

Onkologické oddělení Masarykovy nemocnice Ústí nad Labem, Krajská zdravotní a. s.

Metastatic breast cancer is an incurable disease with a defined time of survival. This time is limited to only a few months when

visceral metastases are present. Chemotherapy is the crucial treatment for patients with visceral involvement, symptomatic and

hormone-independent disease. There is a role as well for an antiangiogenic therapy with bevacizumab in HER2-negative disease.

Bevacizumab is approved for the treatment of metastatic HER2-negative breast cancer in combination with paclitaxel. This approval

is based on significant improvement in PFS reported in phase III trial E2100.

Case report: 53-years old patient, female, was diagnosed with triple-negative breast cancer in 2008. Chemotherapy was delivered

in neoadjuvant setting, followed by radical mastectomy with dissection of axilla. Pathological staging was ypT1a ypN1. Adjuvant

chemotherapy was applied as well as radiation therapy. In May 2012 the evidence of metastatic disease in lung and mediastinal

lymph nodes was proved by CT scan. Triple negative breast cancer was verified from bronchology exam. FISH analysis of HER2 was

also negative. Combination treatment with paclitaxel + bevacizumab was indicated. There is an evidence of complete remission

of disease. Up to date the survival is 43 months a quality of life is excellent.

Keywords: triple negative breast cancer, bevacizumab, paclitaxel, case report

Published: March 1, 2016  Show citation